Study shows Novartis’ Cosentyx may modify course of psoriasis
Novartis has unveiled trial results which it says show that Cosentyx is the first and only IL-17A inhibitor to potentially modify the course of psoriasis.
Read More
Tag: STEPIn
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
